The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of chemotherapy for patients with unresectable pancreatic cancer concomitant with collagen disease: A multicenter retrospective observational study.
 
Hiroyuki Asama
No Relationships to Disclose
 
Hiroyuki Okuyama
Honoraria - AstraZeneca; Novartis
Consulting or Advisory Role - Novartis
 
Yasuyuki Kawamoto
Honoraria - AstraZeneca; Incyte; Lilly Japan; Merck; Nihon Servier; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Taiho Pharmaceutical
Research Funding - Japan Agency for Medical Research and Development; Takeda
 
Kumiko Umemoto
Honoraria - Taiho Pharmaceutical; Taiho Pharmaceutical
 
Takuo Yamai
No Relationships to Disclose
 
Satoshi Kobayashi
Honoraria - AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; Lilly; Otsuka; Taiho Pharmaceutical; Takeda; Yakult Honsha; Zymeworks
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Eisai (Inst); Incyte (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Masafumi Watanabe
No Relationships to Disclose
 
Yasuo Hamamoto
Consulting or Advisory Role - Chugai Pharma; Dainippon Sumitomo Pharma
Research Funding - Bristol-Myers Squibb Japan; Lilly Japan; MSD Oncology; Ono Pharmaceutical
 
Takaaki Furukawa
Consulting or Advisory Role - Novartis
 
Yohei Kitano
No Relationships to Disclose
 
Masayo Motoya
No Relationships to Disclose
 
Yuko Suzuki
No Relationships to Disclose
 
Akihiro Ohba
Honoraria - AstraZeneca; Eisai; Guardant Health; Ono Pharmaceutical; SERVIER; Yakult Honsha
Consulting or Advisory Role - Zymeworks
Research Funding - Chugai Pharma (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Kazuo Watanabe
No Relationships to Disclose
 
Naohiro Okano
Honoraria - AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Eisai; Incyte Japan; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Kazuhiko Shioji
No Relationships to Disclose
 
Noritoshi Kobayashi
Honoraria - Novartis
Research Funding - Novartis
 
Hiroshi Imaoka
Honoraria - AstraZeneca; Kaneka Medix; Nihon Servier; SB-KAWASUMI LABORATORIES; Yakult Honsha
Consulting or Advisory Role - Nihon Servier
Research Funding - Novartis (Inst); Ono Pharmaceutical (Inst)
 
Takeshi Terashima
Speakers' Bureau - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
 
Makoto Ueno
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Incyte; J-pharma; MSD; Mylan; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Boehringer Ingelheim; Novocure
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); Incyte (Inst); J-pharma (Inst); JPH Clinical Development (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)